about
Impaired prefrontal synaptic gain in people with psychosis and their relatives during the mismatch negativity.Neuronal Surface Autoantibodies in Neuropsychiatric Disorders: Are There Implications for Depression?The production of viral vectors designed to express large and difficult to express transgenes within neurons.Alzheimer's disease and gut microbiota.Human gut microbiota: the links with dementia developmentThe Relative Contribution of NMDARs to Excitatory Postsynaptic Currents is Controlled by Ca(2+)-Induced Inactivation.Alzheimer's disease and the microbiome.Endosomal pH in neuronal signaling and synaptic transmission: role of Na(+)/H(+) exchanger NHE5.Glix 13, a new drug acting on glutamatergic pathways in children and animal models of autism spectrum disordersThe gastrointestinal tract microbiome and potential link to Alzheimer's disease.Pathogen-mediated NMDA receptor autoimmunity and cellular barrier dysfunction in schizophrenia.Role of gut microbiota and nutrients in amyloid formation and pathogenesis of Alzheimer disease.The Gut Microbiota and Alzheimer's Disease.Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis.Neuropsychopharmacology of psychosis: relation of brain signals, cognition, and chemistry.Polyunsaturated fatty acid deficiency during neurodevelopment in mice models the prodromal state of schizophrenia through epigenetic changes in nuclear receptor genesThe bioactive protein-ligand conformation of GluN2C-selective positive allosteric modulators bound to the NMDA receptor.Attenuation of reserpine-induced pain/depression dyad by gentiopicroside through downregulation of GluN2B receptors in the amygdala of mice.Recording Brain Electromagnetic Activity During the Administration of the Gaseous Anesthetic Agents Xenon and Nitrous Oxide in Healthy Volunteers.Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study.Pathogenicity of lupus anti-ribosomal P antibodies: role of cross-reacting neuronal surface P antigen in glutamatergic transmission and plasticity in a mouse model.Nutritional modulation of the intestinal microbiota; future opportunities for the prevention and treatment of neuroimmune and neuroinflammatory disease
P2860
Q30384905-A4F6B69D-F134-4AFB-97AA-8A096673FBC2Q33871737-FC24DCBA-6FB9-4E80-B741-34064A59210DQ35177199-8CF6A5C9-FE8B-4B4A-B2CE-7C21DCC2DDB1Q36114884-82C57BAC-CB8B-4905-8919-97E727799884Q36198753-4AF65B57-C6EC-479E-A433-C2B0C8E3B79BQ36516436-946A1526-60E2-405F-B2C1-EE5A3630C062Q37178073-B240A404-625C-4EA1-9774-8E7259F65294Q38181077-D697053D-88B0-4FE2-8FD7-F18DA10164E6Q38194145-66B6A490-5839-4E58-B911-B80D43EEC999Q38207585-E6FB5272-1597-4F54-9C9D-C623798A2C29Q38649487-37BA0B2A-AA4C-41DF-B0B9-688022CC718DQ38955990-271C2A42-458B-4CB3-8CEC-960562F0AB4CQ39217126-B4ABEBC2-849E-4AE5-85AC-82BAD41DF78FQ39308929-E2C5CB36-7BEA-4708-8245-575E8E1B1646Q41548616-9D7ABD19-3605-48FD-A7F0-CCC1A444C213Q42257168-16E82AD4-3DE7-45AA-9ADF-6200AB4D19FCQ47292153-94A57D9F-E6B2-47CC-8F9F-FB2A0AA373B7Q47794274-E68E4A62-2214-4F02-9BCA-6AC8348A5B56Q47842719-851AE67E-7C50-46DD-A9D2-A6D5D01DC030Q48117897-7C870FA9-9BFF-4551-9BD0-D8303C3FCEBDQ48313467-0C5B087E-B10F-41E8-BFAD-1A6B4A12D9CBQ61847159-43d8ed88-4bf5-9525-16c7-9f3e34bcc1ed
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
NMDA Receptor Activity in Neuropsychiatric Disorders.
@en
type
label
NMDA Receptor Activity in Neuropsychiatric Disorders.
@en
prefLabel
NMDA Receptor Activity in Neuropsychiatric Disorders.
@en
P2860
P356
P1476
NMDA Receptor Activity in Neuropsychiatric Disorders.
@en
P2093
Mario Caro
Norell Hadzimichalis
P2860
P356
10.3389/FPSYT.2013.00052
P577
2013-06-10T00:00:00Z